HIV pill combo simplifies treatment for patients over 45
NCT ID NCT02212379
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a two-drug combination of raltegravir and etravirine in 170 adults with HIV who were at least 45 years old and already had the virus well-controlled. Participants switched from a standard three-drug regimen to this simpler two-pill combo. After 96 weeks, over 98% still had undetectable virus levels, suggesting this approach could be a safe and effective option for older adults living with HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
raltegravir and etravirine (oral tablets)
What this could lead to
If successful, this could offer a simpler, two-drug option for older adults with HIV, reducing pill burden and side effects while keeping the virus suppressed.
What could go wrong
This was a small, single-arm phase II study with no comparison group. Results may not apply to all patients, and long-term risks or resistance are still unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Hôtel Dieu
Nantes, 44093, France
-
Hospital Clinic
Barcelona, 08036, Spain
-
Hospital de Bellvitge
Barcelona, 08000, Spain
-
Hospital de la santa Creu i San Pau
Barcelona, 08025, Spain
-
Hôpital Avicenne
Bobigny, 93000, France
-
Hôpital Bichat Claude Bernard
Paris, 75018, France
-
Hôpital Bicêtre
Le Kremlin-Bicêtre, 94275, France
-
Hôpital Bretonneau
Tours, 37044, France
-
Hôpital Cochin
Paris, 75014, France
-
Hôpital Croix Rousse
Lyon, 69317, France
-
Hôpital Européen Georges Pompidou
Paris, 75908, France
-
Hôpital Gui de Chauliac
Montpellier, 34000, France
-
Hôpital Jean Verdier
Bondy, 93140, France
-
Hôpital Necker
Paris, 75015, France
-
Hôpital Pitié-Salpétrière
Paris, 75013, France
-
Hôpital Saint André
Bordeaux, 33076, France
-
Hôpital Saint Louis
Paris, 75010, France
-
Hôpital Sainte marguerite
Marseille, 13009, France
-
Hôpital de l'Archet
Nice, 06202, France